Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315671 | 1.00 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL26553755 | 1.00 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL1582583 | 1.00 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL29138069 | 0.93 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL26553775 | 0.93 | TAS1R3 (0.54) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL26298181 | 0.93 | TAS1R3 (0.54) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL23679990 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA3 | |
| SCHEMBL21878146 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA3 | |
| SCHEMBL22883375 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA3 | |
| SCHEMBL23425430 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104647-A1 | VACCINE | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | WO | disclosed |
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-12269841-B2 | Production method for oligonucleotides | AJINOMOTO CO., INC. (JP) | 2025-04-08 | — | — | US | disclosed |
| EP-4522628-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250041400-A1 | RSV VACCINE | ASTRAZENECA PHARMACEUTICALS LP | 2025-02-06 | — | — | US | disclosed |
| WO-2025017142-A1 | RSV VACCINE | ASTRAZENECA AB (SE) | 2025-01-23 | — | — | WO | disclosed |
| US-5914396-A | 2'-O-modified nucleosides and phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| EP-0260032-B1 | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers | AJINOMOTO KK (JP) | 1994-01-26 | — | — | EP | disclosed |
| EP-0260032-A2 | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers | AJINOMOTO CO., INC. (JP) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | POLRMT, TARDBP, NSUN2 | KDM4E 4724/4885TAS1R3 4394/4885TAS1R1 4196/4885 |
| US-20250041400-A1 | RSV VACCINE | LSS, SLFN12, FDPS | KDM4E 3051/4885TAS1R3 4604/4885TAS1R1 4646/4885 |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | UMPS, PNP, NUDT1 | KDM4E 721/4885TAS1R3 4311/4885TAS1R1 4236/4885 |
| US-12269841-B2 | Production method for oligonucleotides | RNGTT, DCLRE1B, PHOSPHO1 | KDM4E 2580/4885TAS1R3 4770/4885TAS1R1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.